Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
R-CHOP
58%
Overall Survival
53%
Progression-free Survival
52%
Multiple Myeloma
46%
Risk Factors
36%
Myeloma
32%
Chimeric Antigen Receptor T Cells (CAR-T)
31%
Prognostic Value
31%
Cyclophosphamide
30%
Single Center
30%
Febrile Neutropenia
30%
Follicular Lymphoma
30%
B-cell non-Hodgkin Lymphoma (B-NHL)
30%
95% Confidence Interval
27%
Multivariate Analysis
26%
Rituximab
25%
Poor Prognosis
25%
Hazard Ratio
25%
Multiple Myeloma Patients
23%
Japanese Patients
23%
Granulocyte Colony-stimulating Factor (G-CSF)
22%
Doxorubicin
21%
Prognostic Factors
20%
Thymidine Kinase Activity
20%
NHL-2
20%
Anemia
20%
Bortezomib
20%
Peripheral T-cell Lymphoma
20%
Rituximab Maintenance
20%
Working Diagnosis
18%
Newly Diagnosed
18%
Chemotherapy
17%
Malignant Lymphoma
17%
Prednisolone
15%
Central Nervous System Relapse
15%
Prednisone
14%
Maintenance Group
14%
Newly Diagnosed Patients
13%
Japan
13%
Newly Diagnosed multiple Myeloma
12%
Soluble interleukin-2 Receptor (sIL-2R)
12%
Poor Prognostic Marker
12%
C-reactive Protein
11%
Hematopoietic Stem Cells
11%
Aggressive Lymphoma
11%
Relapse-free Survival
11%
Apoptosis Induction
11%
Prognostic Impact
11%
Dose Reduction
10%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
89%
Rituximab
51%
Overall Survival
45%
Chemotherapy
36%
Myeloma
30%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
24%
Vincristine
24%
Progression Free Survival
23%
Multiple Myeloma
22%
Follicular Lymphoma
20%
Anemia
20%
Central Nervous System
20%
Multivariate Analysis
19%
Hazard Ratio
17%
Prognostic Factor
17%
Cyclophosphamide
15%
Doxorubicin
15%
Recurrence Free Survival
14%
Diseases
14%
Monocyte
12%
C Reactive Protein
11%
Lactase
11%
Oxidoreductase
11%
Prednisolone
11%
Aggressive Lymphoma
10%
Stomach Mucosa
10%
Immunohistochemistry
10%
Biological Marker
10%
Disease Course
10%
MALT Lymphoma
10%
Urothelial Cancer
10%
Histone Deacetylase
10%
Large-Cell Lymphoma
10%
Retrospective Study
10%
T-Helper Cell
10%
Retrospective Cohort Study
10%
Tumor Lysis Syndrome
10%
Pembrolizumab
10%
Cell Count
10%
Cell Fate
10%
Cisplatin
10%
Thymidine Kinase
10%
Neuroendocrine Carcinoma
10%
Irinotecan
10%
Oral Mucositis
10%
Bortezomib
10%
Lactate Dehydrogenase
8%
Median Follow Up
7%
Adverse Event
7%
Malignant Neoplasm
6%